HUP0100568A2 - 11béta-Halogén-7alfa-helyettesített-ösztratriének, alkalmazásuk gyógyászati készítmények előállítására, valamint ilyen vegyületeket tartalmazó gyógyászati készítmények - Google Patents
11béta-Halogén-7alfa-helyettesített-ösztratriének, alkalmazásuk gyógyászati készítmények előállítására, valamint ilyen vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0100568A2 HUP0100568A2 HU0100568A HUP0100568A HUP0100568A2 HU P0100568 A2 HUP0100568 A2 HU P0100568A2 HU 0100568 A HU0100568 A HU 0100568A HU P0100568 A HUP0100568 A HU P0100568A HU P0100568 A2 HUP0100568 A2 HU P0100568A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- general formula
- pharmaceutical compositions
- alkenylene
- alkylene
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 150000002164 estratrienes Chemical class 0.000 title 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000004419 alkynylene group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 239000004215 Carbon black (E152) Chemical group 0.000 abstract 1
- 206010067572 Oestrogenic effect Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 201000008275 breast carcinoma Diseases 0.000 abstract 1
- 229910052801 chlorine Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229930195733 hydrocarbon Chemical group 0.000 abstract 1
- 150000002430 hydrocarbons Chemical group 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány (I) általános képletű 11<-halogén-7a-helyettesített-ösztratrién vegyületekre vonatkozik, a képletben R3 jelentésehidrogénatom, szénhidrogén- vagy acilcsoport, R11 jelentése fluor-vagy klóratom, R7 jelentése -A-B-Z-R20 általános képletű csoport,amelyben A jelentése közvetlen vegyértékkötés, benzilidén- vagyfeniléncsoport, B jelentése alkilén-, alkenilén- vagyalkiniléncsoport, Z jelentése -NR21- vagy -SOx- általános képletű csoport, R20jelentése hidrogénatom, alkil-, alkenil- vagy alkinilcsoport vagy egy-D-CnF2n+1 általános képletű csoport, ahol D jelentése alkilén-,alkenilén- vagy alkiniléncsoport és n értéke 1-8, -L-CH=CF-CpF2p+1általános képletű csoport, ahol L jelentése alkilén-, alkenilén- vagyalkiniléncsoport és p értéke 2-7, -D-O-(CH2)q-aril általános képletűcsoport, ahol D jelentése a fentebb megadott, q értéke 0, 1, 2 vagy 3,és az aril jelentése egy adott esetben helyettesített fenil-, naftil-vagy heteroarilcsoport, -D-O-(CH2)r-CnF2n+1 általános képletű csoport,ahol D és n jelentése a fentebb megadott és r értéke 1-5, vagy R20 ésR21 a nitrogénatommal, amelyhez kapcsolódnak, heterociklusos csoportotképez; R17 jelentése hidrogénatom vagy egy R17'-C(O)- képletű csoport.A találmány szerinti vegyületek antiösztrogén vagy ösztrogén hatásúak,így különböző ösztrogénfüggő betgegségek (pl. emlőkarcinóma,prosztatarák, terméketlenség stb.) kezelésére alkalmazhatók. Atalálmány tárgyához tartoznak még a fenti vegyületeket tartalmazógyógyszerkészítmények. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997158390 DE19758390A1 (de) | 1997-12-23 | 1997-12-23 | 11ß-Halogen-7alpha-substituierte-Estratriene, Verfahren zur Herstellung pharmazeutischer Präparate, die diese 11ß-Halogen-7alpha-substituierte Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE1998106357 DE19806357A1 (de) | 1998-02-10 | 1998-02-10 | 11beta-Halogen-7alpha-substituierte-Estratriene, Verfahren zur Herstellung pharmazeutischer Präparate, die diese 11beta-Halogen-7alpha-substituierte Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
PCT/EP1998/008470 WO1999033855A1 (de) | 1997-12-23 | 1998-12-23 | 11β-HALOGEN-7α-SUBSTITUIERTE-ESTRATRIENE, VERFAHREN ZUR HERSTELLUNG PHARMAZEUTISCHER PRÄPARATE, DIE DIESE 11β-HALOGEN-7α-SUBSTITUIERTE-ESTRATRIENE ENTHALTEN, SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0100568A2 true HUP0100568A2 (hu) | 2001-08-28 |
HUP0100568A3 HUP0100568A3 (en) | 2002-01-28 |
Family
ID=26042916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0100568A HUP0100568A3 (en) | 1997-12-23 | 1998-12-23 | 11beta-halogen-7alpha-substituted estratrienes, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them |
Country Status (27)
Country | Link |
---|---|
US (1) | US6780855B2 (hu) |
EP (1) | EP1042355B1 (hu) |
JP (1) | JP2001527088A (hu) |
KR (1) | KR20010024806A (hu) |
CN (1) | CN1131235C (hu) |
AR (1) | AR015500A1 (hu) |
AT (1) | ATE232543T1 (hu) |
AU (1) | AU750801B2 (hu) |
BG (1) | BG104553A (hu) |
BR (1) | BR9814416A (hu) |
CA (1) | CA2316444A1 (hu) |
DE (1) | DE59807213D1 (hu) |
DK (1) | DK1042355T3 (hu) |
EA (1) | EA002623B1 (hu) |
EE (1) | EE200000380A (hu) |
ES (1) | ES2191371T3 (hu) |
HU (1) | HUP0100568A3 (hu) |
ID (1) | ID26207A (hu) |
IL (1) | IL136938A0 (hu) |
IS (1) | IS5526A (hu) |
NO (1) | NO20003286L (hu) |
NZ (1) | NZ505348A (hu) |
PE (1) | PE20000129A1 (hu) |
PL (1) | PL341299A1 (hu) |
SK (1) | SK9442000A3 (hu) |
TR (1) | TR200001973T2 (hu) |
WO (1) | WO1999033855A1 (hu) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032429A2 (en) * | 2000-10-18 | 2002-04-25 | Schering Aktiengesellschaft | Use of inhibitors of progesterone receptor for treating cancer |
AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
CA2539502A1 (en) * | 2003-10-14 | 2005-04-21 | Council Of Scientific And Industrial Research | (3r,4r)-trans-3,4-diarylchroman derivatives with estrogenic activity |
US7790910B2 (en) * | 2004-07-27 | 2010-09-07 | Sicor Inc. | Process for the preparation of 7α-alkylated 19-norsteroids |
AU2006317486B9 (en) | 2005-11-22 | 2011-08-04 | Sumitomo Chemical Company, Limited | Organic sulfur compounds and use thereof as arthropodicides |
DE102007049630A1 (de) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
DE102007023614A1 (de) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
JP5298631B2 (ja) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | 有機硫黄化合物及びその有害節足動物防除用途 |
TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
JP2009001551A (ja) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | 有機硫黄化合物及びその有害節足動物防除用途 |
DE102007032800A1 (de) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
EP2033948A1 (en) * | 2007-08-30 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation |
CA2702710C (en) | 2007-10-16 | 2013-05-07 | Repros Therapeutics, Inc. | Trans-clomiphene for metabolic syndrome |
EP2053055A1 (de) * | 2007-10-24 | 2009-04-29 | Bayer Schering Pharma Aktiengesellschaft | 11.beta.-Fluoro-3-acetoxyestra-3,5-dien-17-on und Verfahren zu seiner Herstellung |
DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
EP2070942A1 (de) | 2007-12-13 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Aromatisierung von 19-Nor-androst-4-en-3-onen zu Estra-1,3,5(10)-trienen |
EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
EP2070909A1 (de) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Nichtsteroidale Progesteronrezeptor-Modulatoren |
EP2258375A1 (de) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratriene |
DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
ES2681023T3 (es) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Terapia de combinación para tratar el déficit de andrógenos |
EP2983671B1 (en) | 2013-04-11 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Progesterone receptor antagonist dosage form |
EP2987799B1 (en) * | 2013-04-18 | 2020-04-08 | Xi'an Libang Pharmaceutical Technology Co.,ltd. | Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof |
CN104387435B (zh) * | 2014-12-10 | 2017-05-10 | 天津孚音生物科技发展有限公司 | 一种化合物及其制备方法与应用 |
CN106146599A (zh) * | 2015-04-07 | 2016-11-23 | 江苏希迪制药有限公司 | 一种回收因亚砜构型比例不合格的氟维司群或其衍生物的方法 |
CN108348605B (zh) | 2015-11-10 | 2023-06-09 | 帕拉卡林治疗公司 | 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌 |
CN112778089B (zh) * | 2021-01-04 | 2023-09-05 | 万知科技股份有限公司 | 一种4,4,4-三氟-1-丁醇及其同系物的新合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3076829A (en) * | 1961-09-15 | 1963-02-05 | Schering Corp | Novel 9, 11-disubstituted estratriene derivatives |
GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
US5866560A (en) * | 1996-08-20 | 1999-02-02 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
-
1998
- 1998-12-18 PE PE1998001246A patent/PE20000129A1/es not_active Application Discontinuation
- 1998-12-18 AR ARP980106471A patent/AR015500A1/es not_active Application Discontinuation
- 1998-12-23 SK SK944-2000A patent/SK9442000A3/sk unknown
- 1998-12-23 NZ NZ505348A patent/NZ505348A/xx unknown
- 1998-12-23 EE EEP200000380A patent/EE200000380A/xx unknown
- 1998-12-23 CN CN98812631A patent/CN1131235C/zh not_active Expired - Fee Related
- 1998-12-23 AT AT98966410T patent/ATE232543T1/de not_active IP Right Cessation
- 1998-12-23 IL IL13693898A patent/IL136938A0/xx unknown
- 1998-12-23 DE DE59807213T patent/DE59807213D1/de not_active Expired - Fee Related
- 1998-12-23 ES ES98966410T patent/ES2191371T3/es not_active Expired - Lifetime
- 1998-12-23 JP JP2000526531A patent/JP2001527088A/ja active Pending
- 1998-12-23 ID IDW20001234A patent/ID26207A/id unknown
- 1998-12-23 HU HU0100568A patent/HUP0100568A3/hu unknown
- 1998-12-23 BR BR9814416-2A patent/BR9814416A/pt not_active IP Right Cessation
- 1998-12-23 US US09/380,413 patent/US6780855B2/en not_active Expired - Fee Related
- 1998-12-23 TR TR2000/01973T patent/TR200001973T2/xx unknown
- 1998-12-23 DK DK98966410T patent/DK1042355T3/da active
- 1998-12-23 AU AU22763/99A patent/AU750801B2/en not_active Ceased
- 1998-12-23 CA CA002316444A patent/CA2316444A1/en not_active Abandoned
- 1998-12-23 EA EA200000711A patent/EA002623B1/ru not_active IP Right Cessation
- 1998-12-23 EP EP98966410A patent/EP1042355B1/de not_active Expired - Lifetime
- 1998-12-23 PL PL98341299A patent/PL341299A1/xx unknown
- 1998-12-23 WO PCT/EP1998/008470 patent/WO1999033855A1/de not_active Application Discontinuation
- 1998-12-23 KR KR1020007006955A patent/KR20010024806A/ko not_active Application Discontinuation
-
2000
- 2000-06-09 IS IS5526A patent/IS5526A/is unknown
- 2000-06-22 NO NO20003286A patent/NO20003286L/no not_active Application Discontinuation
- 2000-06-23 BG BG104553A patent/BG104553A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
EP1042355B1 (de) | 2003-02-12 |
NZ505348A (en) | 2002-10-25 |
AR015500A1 (es) | 2001-05-02 |
BR9814416A (pt) | 2000-10-10 |
SK9442000A3 (en) | 2001-04-09 |
EA200000711A1 (ru) | 2001-02-26 |
EE200000380A (et) | 2001-12-17 |
ATE232543T1 (de) | 2003-02-15 |
EP1042355A1 (de) | 2000-10-11 |
US6780855B2 (en) | 2004-08-24 |
ID26207A (id) | 2000-12-07 |
DK1042355T3 (da) | 2003-04-22 |
PE20000129A1 (es) | 2000-03-11 |
AU2276399A (en) | 1999-07-19 |
TR200001973T2 (tr) | 2001-01-22 |
CN1131235C (zh) | 2003-12-17 |
AU750801B2 (en) | 2002-07-25 |
CN1286693A (zh) | 2001-03-07 |
EA002623B1 (ru) | 2002-06-27 |
IL136938A0 (en) | 2001-06-14 |
WO1999033855A1 (de) | 1999-07-08 |
US20030069434A1 (en) | 2003-04-10 |
NO20003286D0 (no) | 2000-06-22 |
DE59807213D1 (de) | 2003-03-20 |
NO20003286L (no) | 2000-08-23 |
JP2001527088A (ja) | 2001-12-25 |
IS5526A (is) | 2000-06-09 |
HUP0100568A3 (en) | 2002-01-28 |
PL341299A1 (en) | 2001-04-09 |
ES2191371T3 (es) | 2003-09-01 |
CA2316444A1 (en) | 1999-07-08 |
BG104553A (bg) | 2001-02-28 |
KR20010024806A (ko) | 2001-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0100568A2 (hu) | 11béta-Halogén-7alfa-helyettesített-ösztratriének, alkalmazásuk gyógyászati készítmények előállítására, valamint ilyen vegyületeket tartalmazó gyógyászati készítmények | |
PT1263725E (pt) | Novos compostos | |
IS6658A (is) | Ný efnasambönd | |
CY1105957T1 (el) | Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
SE9902987D0 (sv) | Novel compounds | |
HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
AR023727A1 (es) | Compuestos empleados en el tratamiento de padecimientos inflamatorios | |
ATE469892T1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
PT652868E (pt) | Inibidores da fosfodiesterase do amp ciclico | |
CY1108578T1 (el) | Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων | |
BR0009338A (pt) | Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença | |
HUP0300203A2 (en) | Novel cyclic amide derivatives, and pharmaceutical compositions containing same | |
BR0211305A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto | |
HUP0102549A2 (hu) | Platinakomplex, a komplexek előállítása és gyógyászati alkalmazása | |
SE0302139D0 (sv) | Novel compounds | |
DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
IS5588A (is) | Æxliseyðandi miðlar | |
BR9913183A (pt) | Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica | |
MXPA02012426A (es) | Compuestos nuevos. | |
BG101442A (en) | New taxoids, their preparation and pharmaceutical compositions containing them | |
HUP0302629A2 (hu) | Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére | |
DE60144246D1 (de) | Imidazolderivate, verfahren zu deren herstellung und deren verwendung | |
ES466795A1 (es) | Un procedimiento para la produccion de imidazo(1,5-b)pirida-zinas |